Development of Tivantinib as Treatment for Hepatocellular Carcinoma
Open Access
- 1 September 2013
- journal article
- review article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 1 (1), 75-8
- https://doi.org/10.14218/JCTH.2013.00008
Abstract
JCTH,Journal of Clinical and Translational HepatologyKeywords
This publication has 17 references indexed in Scilit:
- Targeting the HGF-cMET Axis in Hepatocellular CarcinomaInternational Journal of Hepatology, 2013
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 studyThe Lancet Oncology, 2012
- Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic StudiesJournal of Clinical Oncology, 2011
- The changing pattern of epidemiology in hepatocellular carcinomaDigestive and Liver Disease, 2010
- ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor ActivityMolecular Cancer Therapeutics, 2010
- Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?Clinical Cancer Research, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotypeJCI Insight, 2006
- Met provides essential signals for liver regenerationProceedings of the National Academy of Sciences of the United States of America, 2004
- Oncogenic kinase signallingNature, 2001